New 'Living Drug' trial targets tough cancers
NCT ID NCT06885697
Summary
This study is testing a new type of personalized cell therapy called TNhYP218 CAR T cells in adults with advanced solid tumors, including mesothelioma, that have come back or spread after standard treatment. Doctors take a participant's own immune cells, modify them in a lab to better target a protein called mesothelin found on many cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose and see if the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.